International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium
- PMID: 32007209
- DOI: 10.1016/S1470-2045(19)30790-9
International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium
Abstract
Patient-reported outcomes (PROs), such as symptoms, function, and other health-related quality-of-life aspects, are increasingly evaluated in cancer randomised controlled trials (RCTs) to provide information about treatment risks, benefits, and tolerability. However, expert opinion and critical review of the literature showed no consensus on optimal methods of PRO analysis in cancer RCTs, hindering interpretation of results. The Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium was formed to establish PRO analysis recommendations. Four issues were prioritised: developing a taxonomy of research objectives that can be matched with appropriate statistical methods, identifying appropriate statistical methods for PRO analysis, standardising statistical terminology related to missing data, and determining appropriate ways to manage missing data. This Policy Review presents recommendations for PRO analysis developed through critical literature reviews and a structured collaborative process with diverse international stakeholders, which provides a foundation for endorsement; ongoing developments of these recommendations are also discussed.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Similar articles
-
Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials.Clin Trials. 2018 Dec;15(6):624-630. doi: 10.1177/1740774518795637. Epub 2018 Aug 24. Clin Trials. 2018. PMID: 30141714
-
Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures.Lancet Oncol. 2023 Jun;24(6):e270-e283. doi: 10.1016/S1470-2045(23)00157-2. Lancet Oncol. 2023. PMID: 37269858 Review.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.Lancet Oncol. 2018 Sep;19(9):e459-e469. doi: 10.1016/S1470-2045(18)30418-2. Lancet Oncol. 2018. PMID: 30191850
-
Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards.Lancet Oncol. 2016 Nov;17(11):e510-e514. doi: 10.1016/S1470-2045(16)30510-1. Epub 2016 Oct 18. Lancet Oncol. 2016. PMID: 27769798 Review.
Cited by
-
Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018.Health Qual Life Outcomes. 2020 Oct 12;18(1):338. doi: 10.1186/s12955-020-01591-x. Health Qual Life Outcomes. 2020. PMID: 33046106 Free PMC article. Review.
-
15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysis.EClinicalMedicine. 2024 Jan 5;68:102413. doi: 10.1016/j.eclinm.2023.102413. eCollection 2024 Feb. EClinicalMedicine. 2024. PMID: 38273886 Free PMC article.
-
Late Effects after Chimeric Antigen Receptor T cell Therapy for Lymphoid Malignancies.Transplant Cell Ther. 2021 Mar;27(3):222-229. doi: 10.1016/j.jtct.2020.10.002. Epub 2020 Dec 21. Transplant Cell Ther. 2021. PMID: 33928266 Free PMC article. Review.
-
Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial.Eur Urol Oncol. 2022 Oct;5(5):553-563. doi: 10.1016/j.euo.2022.02.003. Epub 2022 Mar 11. Eur Urol Oncol. 2022. PMID: 35288066 Free PMC article. Clinical Trial.
-
Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment.Nat Rev Urol. 2023 Jul;20(7):420-433. doi: 10.1038/s41585-023-00747-w. Epub 2023 Mar 16. Nat Rev Urol. 2023. PMID: 36928615 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous